Les Newsletters de Stop-Tabac.ch

Webmasters - Proposez nos news sur votre site

Rechercher dans les anciennes newsletter:

22 mars 2011

 

La newsletter de stop-tabac: les sujets clés de l?actualité mondiale sur le tabagisme

Sélection réalisée par Jean-François Etter

Le 22 Mars 2011

 


- Journée mondiale sans tabac 2011
- Témoignez à la TV Suisse
- The cost-effectiveness of antidepressants for smoking cessation in chronic obstructive pulmonary disease (COPD) patients
- Chattez avec un médecin tabacologue


Journée mondiale sans tabac 2011

Thème: La Convention-cadre de l'OMS pour la lutte antitabac

http://www.who.int/tobacco/fr/ (11 03 2011) 
(22 03 2011)


Témoignez à la TV Suisse

Pour une émission qui sera diffusée sur la Radio Télévision Suisse, nous sommes à la recherche de témoignages de personnes qui ont:
- Arrêté de fumer grâce à la volonté 
- Arrêté de fumer grâce aux substituts nicotiniques (ou varénicline et bupropion) 
- Arrêté de fumer grâce avec l'aide d'un accompagnement /coach 
- Arrêté du fumer par crainte de maladie 
- Arrêté de fumer grâce aux nouvelles thérapies 


Si vous êtes intéressé-e ou pour tout renseignement merci de contacter Madame Lavdi Buçinca - 022/592.50.00 - 076 216.72 .30 - lbucinca(à)freestudios.ch (remplacez "(à)" par "@") (15 03 2011) 
(22 03 2011)


The cost-effectiveness of antidepressants for smoking cessation in chronic obstructive pulmonary disease (COPD) patients

Objectives In healthy smokers, antidepressants can double the odds of cessation. Because of its four times lower costs and comparable efficacy in healthy smokers, nortriptyline appears to be favourable compared to bupropion. We assessed which of both drugs was most effective and cost-effective in stopping smoking after 1 year compared with placebo among smokers at risk or with existing chronic obstructive pulmonary disease (COPD).

Methods A total of 255 participants, aged 3070 years, received smoking cessation counselling and were assigned bupropion, nortriptyline or placebo randomly for 12 weeks. Prolonged abstinence from smoking was defined as a participant's report of no cigarettes from week 4 to week 52, validated by urinary cotinine. Costs were calculated using a societal perspective and uncertainty was assessed using the bootstrap method.

Results The prolonged abstinence rate was 20.9% with bupropion, 20.0% with nortriptyline and 13.5% with placebo. The differences between bupropion and placebo [relative risk (RR) = 1.6; 95% confidence interval (CI) 0.83.0] and between nortriptyline and placebo (RR = 1.5; 95% CI 0.82.9) were not significant. Severity of airway obstruction did not influence abstinence significantly. Societal costs were 1368 (2.5th97.5th percentile 1935260) with bupropion, 1906 (2.5th97.5th 12017 761) with nortriptyline and 1212 (2.5th97.5th 966602) with placebo. Were society willing to pay more than 2000 for a quitter, bupropion was most likely to be cost-effective.

Conclusions Bupropion and nortriptyline seem to be equally effective, but bupropion appears to be more cost-effective when compared to placebo and nortriptyline. This impression holds using only health care costs. As the cost-effectiveness analyses concern some uncertainties, the results should be interpreted with care and future studies are needed to replicate the findings.

Addiction Volume 104 Issue 12, Pages 2110 - 2117 Published Online: 9 Nov 2009. Constant P. Van Schayck, Janneke Kaper, Edwin J. Wagena, Emiel F. M. Wouters & Johannes L. Severens

http://www3.interscience.wiley.com/journal/122680337/abstract?CRETRY=1&SRETRY=0
(22 03 2011)



Retour à la liste des newsletters